The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model

Osteosarcoma

(2016) Patrick J. Messerschmitt et al.   JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis

(2015) Marion Zillhardt et al.   NEOPLASIA

Osteosarcoma

(2010) Richard Gorlick et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors

(2009) Sergei L. Timofeevski et al.   BIOCHEMISTRY

metoncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre‐clinical model of human osteosarcoma

(2009) Raffaella De Maria et al.   JOURNAL OF PATHOLOGY

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

(2008) U. McDermott et al.   CANCER RESEARCH

Frzb, a Secreted Wnt Antagonist, Decreases Growth and Invasiveness of Fibrosarcoma Cells Associated with Inhibition of Met Signaling

(2008) Y. Guo et al.   CANCER RESEARCH

Specific Tyrosine Kinase Inhibitors Regulate Human Osteosarcoma Cells In vitro

(2008) Patrick J. Messerschmitt et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease

(2008) C. R. Walkley et al.   GENES & DEVELOPMENT

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY

Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage

(2008) S. D. Berman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA